Tech M&A Decline, Gilead's Acquisition of Arcellx, and Merck's Pharma Division Split

The technology sector is experiencing a downturn in mergers and acquisitions, with activity slowing significantly. Bloomberg posted on X, highlighting the recent developments in the industry. In a notable transaction, Gilead Sciences has reached an agreement to acquire Arcellx, a move that underscores its strategic focus on expanding its portfolio in the biotech field. Meanwhile, Merck has announced plans to separate its pharmaceutical division, a strategic decision aimed at enhancing operational efficiency and focusing on core business areas source: https://www.binance.com/en/square/post/294788732666849?utm_source=BinanceNewsRSS